Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2021

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	September 30, 2021
	Valuation									Balance Sheet Classification
(In thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value		Current Assets		Noncurrent Assets
Commercial paper and     corporate bonds	$	9,718	$	2	$	(1	)	$	9,719	$	7,717	$	2,002
Total	$	9,718	$	2	$	(1	)	$	9,719	$	7,717	$	2,002

	September 30, 2020
	Valuation									Balance Sheet Classification
(In thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value		Current Assets		Noncurrent Assets
Commercial paper and     corporate bonds	$	30,313	$	19	$	(19	)	$	30,313	$	30,313	$	—
Total	$	30,313	$	19	$	(19	)	$	30,313	$	30,313	$	—

Components of Inventories

Inventories consisted of the following components:

	September 30,
(In thousands)	2021		2020
Raw materials	$	4,165	$	3,758
Work-in process		1,295		817
Finished products		1,300		1,391
Total	$	6,760	$	5,966

Summary of Prepaids and Other Current Assets

Prepaids and other current assets consisted of the following:

	September 30,
(In thousands)	2021		2020
Prepaid expenses	$	1,712	$	1,418
Irish research and development credits receivable		1,164		1,177
CARES Act employee retention credit receivable		3,577		—
Other		—		775
Prepaids and other	$	6,453	$	3,370

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components:

	Useful Life	September 30,
(Dollars in thousands)	(Years)	2021			2020
Land	N/A	$	4,419		$	4,419
Laboratory fixtures and equipment	3 to 10		29,482			28,600
Buildings and improvements	3 to 20		26,573			25,638
Leasehold improvements	5 to 10		6,499			4,836
Office furniture and equipment	3 to 10		8,713			7,334
Construction-in-progress			2,120			2,238
Less: Accumulated depreciation			(47,716	)		(42,962	)
Property and equipment, net		$	30,090		$	30,103

Schedule of Intangible Assets

Intangible assets consisted of the following:

	September 30, 2021
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	13,216	$	(8,878	)	$	4,338
Developed technology		11.9		36,531		(5,652	)		30,879
Patents and other		14.1		3,551		(2,294	)		1,257
Total definite-lived intangible assets				53,298		(16,824	)		36,474
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	53,878	$	(16,824	)	$	37,054

	September 30, 2020
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	13,356	$	(7,594	)	$	5,762
Developed technology		11.5		9,685		(4,200	)		5,485
Patents and other		14.1		3,551		(2,095	)		1,456
Total definite-lived intangible assets				26,592		(13,889	)		12,703
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	27,172	$	(13,889	)	$	13,283

Estimated Amortization Expense

Based on the intangible assets in service as of September 30, 2021, estimated amortization expense for future fiscal years is as follows:

(In thousands)
2022	$	4,668
2023		4,070
2024		3,978
2025		3,940
2026		2,992
Thereafter		16,826
Definite-lived intangible assets	$	36,474

Schedule of Carrying Amount of Goodwill By Reportable Segment

Changes in the carrying amount of goodwill by segment were as follows:

(In thousands)	In Vitro Diagnostics		Medical Device			Total
Goodwill as of September 30, 2019	$	8,010	$	18,161		$	26,171
Foreign currency translation adjustment		—		1,014			1,014
Goodwill as of September 30, 2020		8,010		19,175			27,185
Acquisition of Vetex Medical Limited		—		19,089			19,089
Foreign currency translation adjustment		—		(668	)		(668	)
Goodwill as of September 30, 2021	$	8,010	$	37,596		$	45,606

Summary of Other Noncurrent Assets

Other noncurrent assets consisted of the following:

	September 30,
(In thousands)	2021		2020
Operating lease right-of-use assets	$	2,435	$	2,508
Other noncurrent assets		1,283		1,761
Other assets, net	$	3,718	$	4,269

Schedule of Accrued Other Liabilities

Accrued other liabilities consisted of the following:

	September 30,
(In thousands)	2021		2020
Accrued professional fees	$	489	$	239
Accrued clinical study expense		1,667		2,206
Accrued purchases		1,195		647
Acquisition of in-process research and development and     intangible assets		494		1,148
Due to customers		112		321
Construction-in-progress		23		272
Operating lease liability, current portion		518		436
Other		407		278
Total accrued other liabilities	$	4,905	$	5,547

Schedule of Other Long-term Liabilities

Other long-term liabilities consisted of the following:

	September 30,
(In thousands)	2021		2020
Deferred consideration (1)	$	5,106	$	2,216
Contingent consideration (2)		817		—
Unrecognized tax benefits (3)		2,538		2,464
Operating lease liabilities		3,188		3,340
Other long-term liabilities	$	11,649	$	8,020

(1) Deferred consideration consists of the present value of guaranteed payments to be made in connection with the fiscal 2021 Vetex acquisition (Note 12) and with in-process R&D technology asset acquisitions in fiscal 2019 and 2018 (Note 11).

(2) Contingent consideration consists of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 5 and Note 12).

(3) Balance of unrecognized tax benefits (Note 9) includes accrued interest and penalties, if applicable.

Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities

Operating lease right-of-use assets and lease liabilities were as follows:

	September 30,
(In thousands)	2021		2020
Right-of-use assets:
Other assets	$	2,435	$	2,508
Operating lease liabilities:
Other accrued liabilities	$	518	$	436
Other long-term liabilities		3,188		3,340
Total operating lease liabilities	$	3,706	$	3,776

Schedule of Operating Lease Maturities

As of September 30, 2021, operating lease maturities were as follows:

(In thousands)
2022	$	657
2023		671
2024		685
2025		699
2026		604
Thereafter		892
Total expected operating lease payments		4,208
Less: Imputed interest		(502	)
Total operating lease liabilities	$	3,706

Denominator for Computation of Diluted Weighted Average Shares Outstanding

The following table presents the denominator for the computation of diluted weighted average shares outstanding:

	Fiscal Year
(In thousands)	2021		2020		2019
Basic weighted average shares outstanding		13,765		13,552		13,389
Dilutive effect of outstanding stock options, non-vested     restricted stock, and non-vested restricted stock units		224		260		390
Diluted weighted average shares outstanding		13,989		13,812		13,779